Loading
Crystal Mackall is a cell therapy pioneer whose team brought GD2 CAR-T to children with brain tumours that had no treatment.
Crystal Mackall is Director of the Stanford Center for Cancer Cell Therapy and Ernest and Amelia Gallo Family Professor at Stanford, within the Stanford Cancer Institute. A paediatric oncologist and immunologist, she leads Stanford's cancer cell therapy programme, whose GD2 CAR-T trial in H3K27M diffuse midline glioma produced the first meaningful responses in that disease. Her papers include the Nature report of GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas and a Nature study showing that c-Jun overexpression in CAR T cells induces exhaustion resistance. She studies CAR-T exhaustion and enhancement across glioma, neuroblastoma and sarcomas.
| Title | Journal | Year |
|---|---|---|
| GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas | Nature | 2022 |
| c-Jun overexpression in CAR T cells induces exhaustion resistance | Nature | 2019 |
Shares GD2-CART01 (Bambino Gesù phase 1/2), Armoured, logic-gated & next-gen CARs, GD2 (disialoganglioside), Neuroblastoma (paediatric).
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy, Glioma & glioblastoma.
Shares Armoured, logic-gated & next-gen CARs, Neuroblastoma (paediatric), CAR-T cell therapy.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy, Glioma & glioblastoma.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares H3 K27M (diffuse midline glioma), Armoured, logic-gated & next-gen CARs, Stanford Health Care / Stanford Cancer Institute, Neuroblastoma (paediatric).
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares Stanford Health Care / Stanford Cancer Institute, CAR-T cell therapy.